EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
13.66
-0.05 (-0.36%)
Jun 26, 2026, 4:00 PM EDT - Market closed
EyePoint Employees
EyePoint had 214 employees as of December 31, 2025. The number of employees increased by 49 or 29.70% compared to the previous year.
Employees
214
Change (1Y)
49
Growth (1Y)
29.70%
Revenue / Employee
$35,579
Profits / Employee
-$1,269,154
Market Cap
1.15B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 678 |
| MannKind | 592 |
| MeiraGTx Holdings | 409 |
| Wave Life Sciences | 317 |
| Xencor | 260 |
| Sana Biotechnology | 142 |
| Cullinan Therapeutics | 109 |
| Lexicon Pharmaceuticals | 81 |
EYPT News
- 12 days ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 18 days ago - EyePoint Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 24 days ago - EyePoint Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - EyePoint Transcript: Stifel 2026 Virtual Ophthalmology Forum - Transcripts
- 5 weeks ago - EyePoint Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials - TheFly
- 6 weeks ago - EyePoint's late-stage eye drug trials to continue after safety panel review - Reuters
- 6 weeks ago - EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data - GlobeNewsWire